| Autor: |
Halmos B; Department of Oncology, Montefiore/Albert Einstein Cancer Center, 2nd floor, 1695 Eastchester Rd, Bronx, NY 10461, USA., Burke T; Center for Observational & Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA., Kalyvas C; Biostatistics & Research Decision Sciences, MSD Europe, Inc., Brussels, 1200, Belgium., Insinga R; Center for Observational & Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA., Vandormael K; Biostatistics & Research Decision Sciences, MSD Europe, Inc., Brussels, 1200, Belgium., Frederickson A; PrecisionHEOR, Oakland, CA 94612, USA., Piperdi B; Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA. |
| Abstrakt: |
Aim: This study indirectly compared the effectiveness of pembrolizumab monotherapy versus nivolumab + ipilimumab in metastatic non-small-cell lung cancer. Materials and methods: A matching-adjusted indirect comparison was conducted using pooled individual patient data from KEYNOTE-024 and KEYNOTE-042 and published aggregate data from CheckMate 227 Part 1A, with platinum doublet chemotherapy as the anchor. Results: After matching, estimated hazard ratios (95% CI) of pembrolizumab monotherapy versus nivolumab + ipilimumab for overall survival and progression-free survival were 1.07 (0.82, 1.39) and 1.16 (0.93, 1.45), respectively. For objective response rate, the estimated risk ratio (95% CI) was 0.93 (0.71, 1.22) and the risk difference (95% CI) was -2.86%(-11.38, 5.67). Conclusion: Matching-adjusted indirect comparison results demonstrated comparable effectiveness between pembrolizumab monotherapy and nivolumab + ipilimumab as first-line therapies for metastatic non-small-cell lung cancer with PD-L1 tumor-proportion score ≥1%. |
